Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.44 |
| ▸ | DDR1 | Q08345 | 4/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.38 |
| ▸ | GCGR | P47871 | 7/20 | 0.38 |
| ▸ | GIPR | P48546 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | BTK | Q06187 | 1/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.36 |
| ▸ | MARS1 | P56192 | 1/20 | 0.36 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3878993 | 0.82 | TRPV1 (0.49) | TRPV1DDR1EPHX2NR1H4GCGR | |
| SCHEMBL4133109 | 0.81 | CNR2 (0.45) | DDR1 | |
| SCHEMBL4913349 | 0.80 | TRPV1 (0.52) | TRPV1DDR1EPHX2NR1H4GCGR | |
| SCHEMBL3880057 | 0.79 | CNR1 (0.39) | DDR1EPHX2NR1H4GCGR | |
| SCHEMBL3111104 | 0.77 | DDR1 (0.44) | DDR1EPHX2NR1H4GCGR | |
| SCHEMBL3100296 | 0.77 | DDR1 (0.45) | DDR1EPHX2NR1H4GCGR | |
| SCHEMBL3107244 | 0.76 | PPARD (0.44) | DDR1EPHX2NR1H4GCGR | |
| SCHEMBL3114639 | 0.76 | THRB (0.39) | DDR1EPHX2 | |
| SCHEMBL3113811 | 0.75 | KCNK2 (0.40) | TRPV1DDR1EPHX2NR1H4GCGR | |
| SCHEMBL3115892 | 0.74 | DDR1 (0.43) | DDR1EPHX2NR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203699-A1 | AMINOMETHYLPYRIDINE DERIVATIVES, METHOD FOR PREPARING SAME AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS | 2009-08-13 | — | — | US | disclosed |
| EP-2010492-A2 | AMINOMETHYL PYRIDINE DERIVATIVES, METHOD FOR PREPARING SAME AND THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2009-01-07 | — | — | EP | disclosed |
| WO-2007119001-A2 | AMINOMETHYL PYRIDINE DERIVATIVES, METHOD FOR PREPARING SAME AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203699-A1 | AMINOMETHYLPYRIDINE DERIVATIVES, METHOD FOR PREPARING SAME AND THERAPEUTIC USE THEREOF | TPMT, QDPR, HNMT | TRPV1 824/4885DDR1 4853/4885EPHX2 1121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.